The Puerto Rico Pharmaceutical Industry Association raised three specific objections to the recently released study evaluating quality results in drug manufacturing plants outside the U.S. mainland, saying, among other things, the findings were “highly questionable.”
The Puerto Rico Manufacturers Association rejected the conclusions of a study released this week language and cultural barriers among the employees in companies located in Puerto Rico and their stateside counterparts may be risk factors causing quality problems in local plants.
Drugs produced in U.S.-owned and operated pharmaceutical manufacturing plants in Puerto Rico are more likely to have quality problems than those produced by the same firm in a matched plant on the mainland, a study released Tuesday by Ohio State University's Fisher College of Business.
A Dow Jones/Factiva content provider since 2014
Subscribe to our Dollars & Sense podcast!
